Reducing bleeding risk in patients on oral anticoagulation therapy

Impact of peri-procedural management of direct oral anticoagulants on pocket haematoma after cardiac electronic device implantation: the StimAOD multicentre prospective study

(2023) Anne-Céline Martin et al.   EUROPACE

Reversal agents for current and forthcoming direct oral anticoagulants

(2023) Nick van Es et al.   EUROPEAN HEART JOURNAL

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

(2022) Anthony P. Carnicelli et al.   CIRCULATION

Anticoagulation and bleeding in the cancer patient

(2022) Andres Escobar et al.   SUPPORTIVE CARE IN CANCER

Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis

(2022) Yung-Chuan Huang et al.   Journal of Personalized Medicine

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

(2022) Vanessa Roldán et al.   Journal of Personalized Medicine

Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

(2022) Diana A. Gorog et al.   THROMBOSIS AND HAEMOSTASIS

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation

(2022) Wallis C.Y. Lau et al.   ANNALS OF INTERNAL MEDICINE

Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing

(2022) Pascal B Meyre et al.   EUROPEAN HEART JOURNAL

Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

(2022) Lorena Martínez-Montesinos et al.   BIOMEDICINE & PHARMACOTHERAPY

Perioperative Management of Vitamin K Antagonists and Direct Oral Anticoagulants

(2022) Sahrish Shah et al.   CHEST

Bleeding Risk Assessment in Patients with Venous Thromboembolism

(2021) Stephan Nopp et al.   Hamostaseologie

Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal

(2021) Maria A. de Winter et al.   THROMBOSIS RESEARCH

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial

(2021) Kazuma Oyama et al.   EUROPEAN HEART JOURNAL

Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants

(2021) Robert Benamouzig et al.   CARDIOVASCULAR DRUGS AND THERAPY

The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review

(2021) David Stevens et al.   EUROPACE

Corrigendum to: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2021) Jan Steffel et al.   EUROPACE

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

(2021) Floris T. M. Bosch et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

(2021) Faizan Khan et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients

(2021) Giulio Francesco Romiti et al.   THROMBOSIS AND HAEMOSTASIS

Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment

(2021) Jiaxi Zhao et al.   PLOS MEDICINE

2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation

(2021) Tze‐Fan Chao et al.   Journal of Arrhythmia

Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta‐analysis

(2020) Hsien‐Cheng Kuo et al.   CLINICAL CARDIOLOGY

Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2020) Arjun K. Pandey et al.   THROMBOSIS AND HAEMOSTASIS

Periprocedural Management of Oral Anticoagulation

(2020) Joseph R. Shaw et al.   MEDICAL CLINICS OF NORTH AMERICA

Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience

(2020) Petra Šinigoj et al.   International Journal of Clinical Pharmacy

Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry

(2020) Rungroj Krittayaphong et al.   Journal of Clinical Medicine

The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation

(2020) Jason G. Andrade et al.   CANADIAN JOURNAL OF CARDIOLOGY

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)

(2020) Gerhard Hindricks et al.   EUROPEAN HEART JOURNAL

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

(2020) Thomas L. Ortel et al.   Blood Advances

The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis

(2020) Kuang-Tsu Yang et al.   International Journal of Environmental Research and Public Health

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients with Atrial Fibrillation in ENGAGE AF-TIMI 48

(2019) David Douglas Berg et al.   CIRCULATION

Importance of risk reassessment in patients with atrial fibrillation in guidelines: Assessing risk as a dynamic process

(2019) Ting-Yung Chang et al.   CANADIAN JOURNAL OF CARDIOLOGY

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)

(2019) Miklos Rohla et al.   BMJ Open

External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry)

(2019) Naoki Mori et al.   AMERICAN JOURNAL OF CARDIOLOGY

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

(2019) Sungha Park et al.   HYPERTENSION

Stroke Risk as a Function of Atrial Fibrillation Duration and CHA 2 DS 2 -VASc Score

(2019) Rachel M. Kaplan et al.   CIRCULATION

The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal

(2019) María Asunción Esteve-Pastor et al.   THROMBOSIS AND HAEMOSTASIS

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

(2019) James D. Douketis et al.   JAMA Internal Medicine

Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study

(2019) Maria Cristina Vedovati et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

C-reactive protein level predicts 30-day mortality and bleeding in patients with venous thromboembolism: A prospective single-center study

(2019) Pablo Demelo-Rodríguez et al.   MEDICINA CLINICA

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

(2019) Shinichi Goto et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis

(2018) Deirdre A. Lane et al.   CLINICAL CARDIOLOGY

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

(2018) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

OUP accepted manuscript

(2018)   EUROPEAN HEART JOURNAL

Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin

(2018) Masahito Kawabori et al.   Journal of Stroke & Cerebrovascular Diseases

Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation

(2018) Tze-Fan Chao et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants

(2018) Z. Wolfe et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors

(2018) Tze-Fan Chao et al.   THROMBOSIS AND HAEMOSTASIS

Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin

(2018) Masahito Kawabori et al.   Journal of Stroke & Cerebrovascular Diseases

Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway

(2018) Marco Proietti et al.   AMERICAN JOURNAL OF MEDICINE

Antithrombotic Therapy for Atrial Fibrillation

(2018) Gregory Y.H. Lip et al.   CHEST

Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision

(2018) Marco Proietti et al.   THROMBOSIS AND HAEMOSTASIS

The ABC pathway: an integrated approach to improve AF management

(2017) Gregory Y. H. Lip   Nature Reviews Cardiology

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation

(2017) Hugh Calkins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

(2017) E. Seiler et al.   THROMBOSIS AND HAEMOSTASIS

Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists

(2017) Gary Raskob et al.   THROMBOSIS AND HAEMOSTASIS

Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores

(2017) Vanessa Roldán et al.   THROMBOSIS AND HAEMOSTASIS

Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial

(2017) María Esteve-Pastor et al.   THROMBOSIS AND HAEMOSTASIS

Stroke prevention in atrial fibrillation: Past, present and future

(2017) Ben Freedman et al.   THROMBOSIS AND HAEMOSTASIS

Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

(2016) Robert P. Giugliano et al.   AMERICAN JOURNAL OF MEDICINE

Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention

(2016) Jason G. Andrade et al.   CANADIAN JOURNAL OF CARDIOLOGY

Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score

(2016) David C. Hostler et al.   CHEST

Antithrombotic Therapy for VTE Disease

(2016) Clive Kearon et al.   CHEST

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment

(2016) Frederikus A. Klok et al.   EUROPEAN RESPIRATORY JOURNAL

Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial

(2016) Keitaro Senoo et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

(2016) Ziad Hijazi et al.   LANCET

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists

(2016) Francesco Violi et al.   MEDICINE

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists

(2016) Walter Ageno et al.   THROMBOSIS AND HAEMOSTASIS

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation

(2016) Fredrik Björck et al.   JAMA Cardiology

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation

(2015) Emily C. O'Brien et al.   EUROPEAN HEART JOURNAL

Patient-reported health preferences of anticoagulant-related outcomes

(2015) Ye Wang et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view

(2015) Björn Böttger et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation

(2015) James D. Douketis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombosis

(2014) G.E. Raskob et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

(2014) J. P. Piccini et al.   EUROPEAN HEART JOURNAL

Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials

(2014) S.K. Kakkos et al.   EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY

The criteria of the Italian Federation of Thrombosis Centres on DOACs: a “real world” application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist

(2014) Doris Barcellona et al.   Internal and Emergency Medicine

Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

(2014) Dominick J. Angiolillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

(2014) Elaine M. Hylek et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment

(2014) Peter Ghijben et al.   PHARMACOECONOMICS

Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement

(2014) Joseph Mathew et al.   THROMBOSIS AND HAEMOSTASIS

Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

(2013) Ammar Majeed et al.   CIRCULATION

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

(2013) J. H. Alexander et al.   EUROPEAN HEART JOURNAL

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis

(2013) T. van der Hulle et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perioperative Management of Antithrombotic Therapy

(2012) James D. Douketis et al.   CHEST

Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists

(2012) Deborah Siegal et al.   CIRCULATION

Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation

(2012) Leif Friberg et al.   CIRCULATION

Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation

(2012) Stavros Apostolakis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Study of Warfarin Patients Investigating Attitudes Toward Therapy Change (SWITCH Survey)

(2011) Shariff Attaya et al.   AMERICAN JOURNAL OF THERAPEUTICS

Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism

(2011) Jan Steffel et al.   EUROPEAN HEART JOURNAL

A New Risk Scheme to Predict Warfarin-Associated Hemorrhage

(2011) Margaret C. Fang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Factors at Admission Associated With Bleeding Risk in Medical Patients

(2010) Hervé Decousus et al.   CHEST

Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial

(2010) Alan Cheng et al.   HEART RHYTHM

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation

(2010) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

(2009) S. SCHULMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment

(2008) Sam Schulman et al.   CHEST

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2008) Stephen D. Wiviott et al.   CIRCULATION

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry

(2008) Nuria Ruíz-Giménez et al.   THROMBOSIS AND HAEMOSTASIS